Active Ingredient History
Loteprednol (as the ester loteprednol etabonate) is a corticosteroid used to treat inflammations of the eye. It is marketed by Bausch and Lomb as Lotemax. It is a topical corticoid anti-inflammatory. It is used in ophthalmic solution for the treatment of steroid responsive inflammatory conditions of the eye such as allergic conjunctivitis, uveitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, and selected infective conjunctivitis’s. Lotemax is less effective than prednisolone acetate 1% in two 28-day controlled clinical studies in acute anterior uveitis, where 72% of patients treated with Lotemax experienced resolution of anterior chamber cells, compared to 87% of patients treated with prednisolone acetate 1%. Lotemax is also indicated for the treatment of post-operative inflammation following ocular surgery. Corticosteroids inhibit the inflammatory response to a variety of inciting agents and probably delay or slow healing. They inhibit the edema, fibrin deposition, capillary dilation, leukocyte migration, capillary proliferation, fibroblast proliferation, deposition of collagen, and scar formation associated with inflammation. There is no generally accepted explanation for the mechanism of action of ocular corticosteroids. However, corticosteroids are thought to act by the induction of phospholipase A2 inhibitory proteins, collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A2. Corticosteroids are capable of producing a rise in intraocular pressure (IOP). Loteprednol etabonate is structurally similar to other corticosteroids. However, the number 20 position ketone group is absent. It is highly lipid soluble, which enhances its penetration into cells. Loteprednol etabonate is synthesized through structural modifications of prednisolone-related compounds so that it will undergo a predictable transformation to an inactive metabolite. Based upon in vivo and in vitro preclinical metabolism studies, loteprednol etabonate undergoes extensive metabolism to inactive carboxylic acid metabolites. Lotemax possesses some adverse reactions associated with ophthalmic steroids include elevated intraocular pressure, which may be associated with optic nerve damage, visual acuity and field defects, posterior subcapsular cataract formation, secondary ocular infection from pathogens including herpes simplex, and perforation of the globe where there is thinning of the cornea or sclera. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
Combination drugs
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Allergy and Immunology (Phase 2)
Blepharitis (Phase 4)
Cataract (Phase 3)
Cataract Extraction (Phase 4)
Chalazion (Phase 4)
Conjunctivitis (Phase 4)
Conjunctivitis, Bacterial (Phase 3)
Contact Lenses (Phase 4)
Corneal Edema (Phase 4)
Corneal Endothelial Cell Loss (Phase 4)
Corneal Opacity (Phase 4)
Dry Eye Syndromes (Phase 4)
Eye Diseases (Phase 1)
Eye Diseases, Hereditary (Phase 4)
Eye Pain (Phase 1)
Fuchs' Endothelial Dystrophy (Phase 4)
General Surgery (Phase 4)
Glaucoma (Phase 4)
Glaucoma, Open-Angle (Phase 4)
Healthy Volunteers (Phase 1)
Hordeolum (Phase 4)
Inflammation ()
Intraocular Pressure (Phase 4)
Keratectomy (Phase 4)
Keratitis (Phase 3)
Keratoconjunctivitis Sicca (Phase 4)
Meibomian Gland Dysfunction (Phase 4)
Neoplasms (Phase 1)
Ocular Hypertension (Phase 4)
Pain (Phase 3)
Pharmacokinetics (Phase 1)
Pseudophakia (Phase 4)
Uveitis (Phase 2)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
